Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Total Non-Current Liabilities (2017 - 2025)

Autolus Therapeutics' Total Non-Current Liabilities history spans 8 years, with the latest figure at $410.5 million for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities rose 15.63% year-over-year to $410.5 million; the TTM value through Dec 2025 reached $410.5 million, up 15.63%, while the annual FY2025 figure was $410.5 million, 15.63% up from the prior year.
  • Total Non-Current Liabilities reached $410.5 million in Q4 2025 per AUTL's latest filing, up from $396.0 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $410.5 million in Q4 2025 to a low of $92.1 million in Q4 2021.
  • Average Total Non-Current Liabilities over 5 years is $258.0 million, with a median of $263.6 million recorded in 2023.
  • Peak YoY movement for Total Non-Current Liabilities: rose 9.39% in 2021, then skyrocketed 123.01% in 2023.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $92.1 million in 2021, then skyrocketed by 107.88% to $191.5 million in 2022, then skyrocketed by 37.64% to $263.6 million in 2023, then skyrocketed by 34.69% to $355.0 million in 2024, then grew by 15.63% to $410.5 million in 2025.
  • Per Business Quant, the three most recent readings for AUTL's Total Non-Current Liabilities are $410.5 million (Q4 2025), $396.0 million (Q3 2025), and $374.0 million (Q2 2025).